Who
Ryan Cohlhepp
President, COO & Interim CEO
Company insider
Files Form 4 as: President, COO & Interim CEO, Bicara Therapeutics.
In numbers
- Trades disclosed
- 94
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $7.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Oct 2025
- Last trade
- 8 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $66K17,500 at $3.79 | filing |
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $320K14,058 at $22.77 | filing |
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $81K3,442 at $23.43 | filing |
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $66K17,500 at $3.79 | filing |
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $320K14,058 at $22.77 | filing |
| 8 Sep 2026filed 10 Sep 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $81K3,442 at $23.43 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $71K18,750 at $3.79 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $525K18,750 at $27.98 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $71K18,750 at $3.79 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $525K18,750 at $27.98 | filing |
| 9 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K536 at $29.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K536 at $29.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $71K18,750 at $3.79 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $657K22,833 at $28.76 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $128K4,306 at $29.80 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.